FY2022 EPS Estimates for Gilead Sciences, Inc. (NASDAQ:GILD) Raised by Cantor Fitzgerald

Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) – Analysts at Cantor Fitzgerald upped their FY2022 earnings per share (EPS) estimates for shares of Gilead Sciences in a research report issued to clients and investors on Wednesday, August 3rd. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings per share of $6.70 for the year, up from their previous forecast of $6.60. Cantor Fitzgerald currently has a “Neutral” rating and a $70.00 price target on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $6.58 per share. Cantor Fitzgerald also issued estimates for Gilead Sciences’ FY2023 earnings at $6.72 EPS.

GILD has been the topic of several other reports. Royal Bank of Canada lifted their target price on Gilead Sciences from $76.00 to $77.00 and gave the stock an “outperform” rating in a report on Tuesday, April 12th. SVB Leerink initiated coverage on Gilead Sciences in a research note on Monday, May 23rd. They set a “market perform” rating and a $68.00 price target for the company. Piper Sandler cut their price target on Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating for the company in a research note on Monday, May 16th. StockNews.com downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Finally, BMO Capital Markets initiated coverage on Gilead Sciences in a research note on Tuesday, June 7th. They set a “hold” rating and a $63.00 price target for the company. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $72.07.

Gilead Sciences Stock Down 1.3 %

Shares of GILD opened at $61.09 on Thursday. The company has a market capitalization of $76.63 billion, a PE ratio of 18.63, a PEG ratio of 0.63 and a beta of 0.34. Gilead Sciences has a 12 month low of $57.17 and a 12 month high of $74.12. The stock’s 50-day moving average price is $61.55 and its two-hundred day moving average price is $61.93. The company has a current ratio of 1.49, a quick ratio of 1.30 and a debt-to-equity ratio of 1.31.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in Gilead Sciences by 2.3% during the 1st quarter. BlackRock Inc. now owns 121,709,365 shares of the biopharmaceutical company’s stock valued at $7,235,622,000 after acquiring an additional 2,748,159 shares during the period. State Street Corp raised its holdings in Gilead Sciences by 1.0% during the 1st quarter. State Street Corp now owns 57,970,959 shares of the biopharmaceutical company’s stock valued at $3,446,374,000 after acquiring an additional 601,690 shares during the period. Capital World Investors raised its holdings in Gilead Sciences by 16.0% during the 1st quarter. Capital World Investors now owns 49,501,852 shares of the biopharmaceutical company’s stock valued at $2,942,905,000 after acquiring an additional 6,820,228 shares during the period. Geode Capital Management LLC raised its holdings in Gilead Sciences by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 22,739,179 shares of the biopharmaceutical company’s stock valued at $1,647,123,000 after acquiring an additional 440,695 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Gilead Sciences by 324.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after acquiring an additional 13,764,169 shares during the period. Hedge funds and other institutional investors own 80.16% of the company’s stock.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Thursday, September 15th will be paid a $0.73 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $2.92 annualized dividend and a yield of 4.78%. Gilead Sciences’s payout ratio is 89.02%.

Gilead Sciences Company Profile

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Stories

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.